{"id":20561,"date":"2024-07-29T01:30:00","date_gmt":"2024-07-29T05:30:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-presente-ses-resultats-financiers-du-premier-semestre-2024-et-fait-le-point-sur-levolution-de-ses-activites\/"},"modified":"2024-07-29T07:48:44","modified_gmt":"2024-07-29T11:48:44","slug":"dbv-technologies-presente-ses-resultats-financiers-du-premier-semestre-2024-et-fait-le-point-sur-levolution-de-ses-activites","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-presente-ses-resultats-financiers-du-premier-semestre-2024-et-fait-le-point-sur-levolution-de-ses-activites\/","title":{"rendered":"DBV Technologies pr\u00e9sente ses r\u00e9sultats financiers du premier semestre 2024 et fait le point sur l\u2019\u00e9volution de ses activit\u00e9s"},"content":{"rendered":"<div class=\"pr-date-globe\">July 29, 2024 01:30 ET<\/div>\n<p align=\"right\">Ch\u00e2tillon, France, 29 juillet (07:30 CEST), 2024<\/p>\n<p align=\"justify\"><strong>DBV Technologies pr\u00e9sente ses r\u00e9sultats financiers du premier semestre 2024 et fait le point sur l\u2019\u00e9volution de ses activit\u00e9s <\/strong><\/p>\n<p align=\"justify\">DBV Technologies (Euronext : DBV \u2013 ISIN : FR0010417345 \u2013 Nasdaq Stock Market : DBVT), une entreprise biopharmaceutique sp\u00e9cialis\u00e9e dans le stade clinique, a annonc\u00e9 aujourd\u2019hui que la soci\u00e9t\u00e9 organisera une conf\u00e9rence t\u00e9l\u00e9phonique et une webdiffusion audio en direct le mardi 30 juillet 2024 \u00e0 23h30 (heure de Paris) afin de pr\u00e9senter les r\u00e9sultats financiers du premier semestre 2024 et de faire le point sur l\u2019\u00e9volution de ses activit\u00e9s.<\/p>\n<p align=\"justify\">Les participants int\u00e9ress\u00e9s peuvent acc\u00e9der \u00e0 cet appel via les num\u00e9ros de t\u00e9l\u00e9conf\u00e9rence ci-dessous et en demandant \u00e0 rejoindre l&rsquo;appel DBV Technologies\u00a0:<\/p>\n<p align=\"justify\">United States: +1-877-346-6112<br \/>\nInternational: +1-848-280-6350<\/p>\n<p align=\"justify\">Une retransmission en direct de la conf\u00e9rence sera disponible sur le site web de la soci\u00e9t\u00e9, dans la section \u00ab\u00a0Investisseurs et Presse\u00a0\u00bb : https:\/\/www.dbvtechnologies.com\/fr\/investor-relations\/. Une rediffusion de la pr\u00e9sentation sera \u00e9galement disponible sur le site web de DBV apr\u00e8s l&rsquo;\u00e9v\u00e9nement.<\/p>\n<p align=\"justify\"><strong>\u00c0 propos de DBV Technologies<\/strong><br \/>\nDBV Technologies est une entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV Technologies se concentre actuellement sur l&rsquo;\u00e9tude de l&rsquo;utilisation de sa plateforme technologique exclusive, Viaskin\u2122, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l&rsquo;anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l&rsquo;immunoth\u00e9rapie \u00e9picutan\u00e9e (EPIT\u2122), la plateforme Viaskin est con\u00e7ue pour dispenser des quantit\u00e9s de microgrammes d&rsquo;un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L&rsquo;EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l&rsquo;allergie sous-jacente d&rsquo;un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l&rsquo;allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s&rsquo;est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d&rsquo;allergies alimentaires. Les programmes d&rsquo;allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec Viaskin Peanut chez les jeunes enfants (de 1 \u00e0 3 ans) et les enfants (de 4 \u00e0 7 ans) allergiques \u00e0 l&rsquo;arachide.<\/p>\n<p align=\"justify\">Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Ch\u00e2tillon, en France, avec des op\u00e9rations nord-am\u00e9ricaines bas\u00e9es \u00e0 Warren, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris (symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 (chacun repr\u00e9sentant une demi-action ordinaire) sont n\u00e9goci\u00e9s sur le Nasdaq Stock Market (symbole: DBVT\u2014 CUSIP: 23306J101).<\/p>\n<p align=\"justify\">Pour plus d\u2019informations, veuillez consulter <a title=\"www.dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=BS19MhwMRHokQjCb218F9chC2JFl-CI9ETB2IR1OQEIcwI9JYQRZJH9gy9t4klNjNd6KKsXded-Mt5SH2zoFY8ddV2FQ7qr1SzA63pTiIJ7ORV89nLMfrkZ4prKFxlse\" target=\"_blank\" rel=\"nofollow noopener\">www.dbv-technologies.com<\/a> et nous contacter sur <a title=\"X (anciennement Twitter)\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=P5Ekmp_gDmyiv_EQtPYAXvSb6wwiBc3dAcFrpFchdgQPkU4vUa2YE8eKFt79zgm5ZA9YrsdYPLohQxDKHKspETZeJGNhYvoCJxwhHkviZgk0pBcD72B4Kqq_mXGv1bOO\" target=\"_blank\" rel=\"nofollow noopener\">X (anciennement Twitter)<\/a> et <a title=\"LinkedIn.\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=hiybrwk3Yff9DMZiL6tGD8LNpPLD3HzZDBIhpKyu3TuutH6C3LRNzgZ_8AgNMUTZJyWbQehHjUhiKooOy0YJgnnLBaobWowaWsIsLnehgqxi8V74j_lD4uYfc0ykpinQ\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn.<\/a><\/p>\n<p align=\"justify\">Viaskin et EPIT sont des marques commerciales de DBV Technologies.<\/p>\n<p align=\"justify\"><strong>Contact avec les investisseurs <\/strong><br \/>\nKatie Matthews<br \/>\nDBV Technologies<br \/>\n<a title=\"katie.matthews@dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=TR1qY1jruorn5ZUF1GsdNvYtfmzxXy7ewm7m9eK2lvKmfpMqz8p_NLNbzo16dg22Z-pERAVMYIBmLOzaWPxHBltZ6iSgEsMsKbUtm3v2nfEuZFOjt8oIyuHNfhtoRm2Uk56PViR1zrBcG7EPB7au3Q==\" target=\"_blank\" rel=\"nofollow noopener\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"justify\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>\nAngela Marcucci<br \/>\nDBV Technologies<br \/>\n<a title=\"angela.marcucci@dbv-technologies.com\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=nZQGnIKJI8fbDdT1lqQVVpwpH7j5vKJu2rF4_z4F5mzeTSu3t44-CVU1VKXJOox9B1lPk6PWBPFt2RkOoZvovozheOHCrZQgGxw8z1CAP_6JRTX4CEia5_Sdnlas7CuhYmytQmeDpTtWKkUwVIXsIQ==\" target=\"_blank\" rel=\"nofollow noopener\">angela.marcucci@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\"><strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li><a title=\"version PDF\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=oihexzMCVmRIiofjr4MJGtGis3v1SWnJiN1MMLy39PmV6mX2mq1yuralUgQ-dsih2r6CsUOVGdgsWPMHWz0tdE_GWMbs674rkfQk1OEiYC2bK5_a0LzO_hau9xWOn456bq1JvD6EMjHj5rJvlRmWJVgSGWi3Oix6DmIYKv7eqfo=\" target=\"_blank\" rel=\"nofollow noopener\">version PDF<\/a><\/li>\n<\/ul>\n<p><img decoding=\"async\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/YTAyZDVmYWYtMzFiMy00MDdiLWJmN2MtMGY0ZmZkZGFkZjgwLTEwMTExNTI=\/tiny\/DBV-Technologies-S-A-.png\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" \/><\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-20561","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/20561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/20561\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=20561"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=20561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}